Intriguingly, our results demonstrated that hypomethylation of MXD3 mediated dysfunctional T-cell phenotypes and shorter life durations of brain cancer, melanoma, metastatic melanoma, leukemia, breast cancer, and kidney renal clear cell carcinoma (KIRC) cohorts. This evidence concerns the gene MXD3 and brain cancer.